Physician profile
Jennifer Bernard
NPI 1275706285
$1,460.90
in general payments reported to CMS, 2019-2025
29 companies · $192 in 2025
The $192 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $443 · 2020: $161 · 2021: $139 · 2022: $88.76 · 2023: $90.29 · 2024: $347 · 2025: $192.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $586 · Education: $42.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $586.15 |
| Education | $42.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $197.54 | 2022-2025 | Omnipod |
| Medtronic Minimed, INC. | $143.67 | 2019-2020 | |
| Tandem Diabetes Care, INC. | $140.74 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Radius Health, INC. | $94.97 | 2019-2021 | |
| Celgene Corporation | $81.02 | 2022-2024 | Reblozyl |
| Amgen INC. | $77.14 | 2019-2024 | Evenity, Prolia |
| Sanofi-Aventis U.S. LLC | $74.18 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $68.45 | 2019-2021 | |
| Amneal Pharmaceuticals LLC | $57.77 | 2019-2021 | |
| Lilly USA, LLC | $53.70 | 2019-2020 | |
| Sequel Med Tech, LLC | $52.54 | 2025 | Twiist |
| Mannkind Corporation | $42.50 | 2025 | |
| Beta Bionics, INC. | $37.58 | 2023-2024 | Ilet Bionic Pancreas |
| Novo Nordisk INC | $37.26 | 2019-2022 | |
| Antares Pharma, INC. | $30.87 | 2024 | Xyosted |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $26.07 | 2020 | |
| Xeris Pharmaceuticals, INC. | $23.71 | 2021 | |
| Shire North American Group INC | $22.51 | 2019 | |
| Abbott Laboratories | $22.10 | 2025 | Freestyle Libre 3 |
| Becton, Dickinson and Company | $20.72 | 2021 | |
| Lifescan, INC. | $19.43 | 2019 | |
| Novartis Pharmaceuticals Corporation | $19.37 | 2023 | |
| Dexcom, INC. | $18.43 | 2023 | Dexcom G6 Transmitter |
| Alexion Pharmaceuticals, INC. | $18.37 | 2025 | Strensiq |
| Corcept Therapeutics | $18.01 | 2019 | |
| Clarus Therapeutics INC. | $17.81 | 2021 | |
| Abbvie INC. | $16.33 | 2020 | |
| Medtronic, INC. | $15.66 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $12.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Bernard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.